Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Bob Trocchi who wrote (1181)	10/25/1999 3:32:00 PM
From: Mike M	Read Replies (1) \| Respond to of 5582

The problem is there is only Gel Tech's word to go by because there are no published studies. For what it's worth, Hensley says the company has studied 104 people and found that Zicam reduces the duration of cold symptoms from 9 days to one and a half. Frankly, that sounds too good to be true. I am sure that this is a problem for the writer. This is precisely why Gary Kehoe initiated and funded a study at two major universities. The results of this study, formatted along the lines of the VPHM study, will likely be published in a journal if they have significant findings...We are not far from release of those findings. That last sentence "too good to be true" was gratuitous and did more to demonstrate bias of the writer of the article than to add credible discussion. It is only too good to be true if it isn't true. This remains to be seen. Regards, Mike